Immunohistochemical and Ultrastructural Features of Neuroendocrine Differentiated Carcinomas of the Prostate: An Immunoelectron Microscopic Study-Reference-Cited by-同舟云学术

Immunohistochemical and Ultrastructural Features of Neuroendocrine Differentiated Carcinomas of the Prostate: An Immunoelectron Microscopic Study

Published:2005-01 Issue:5 Volume:29 Page:367-375
ISSN:0191-3123
Container-title:Ultrastructural Pathology
language:en
Short-container-title:Ultrastructural Pathology

Author:

Hirano Daisaku,Jike Toyoharu,Okada Yasuhiro,Minei Sadatsugu,Sugimoto Shuji,Yamaguchi Kenya,Yoshikawa Tetsuo,Hachiya Takahiko,Yoshida Toshio,Takimoto Yukie

Publisher

Informa UK Limited

Subject

Structural Biology,Pathology and Forensic Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1080/019131290945718

Reference24 articles.

1. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications

2. Neuroendocrine differentiation in prostatic malignancy

3. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate

4. Peptide-Hormone- And Serotonin-Immunoreactive Tumour Cells in Carcinoma of the Prostate

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoplasms of the Prostate;Urologic Surgical Pathology;2020

2. Overview of Genetically Engineered Mouse Models of Prostate Cancer and Their Applications in Drug Discovery;Current Protocols in Pharmacology;2018-06

3. The proliferation marker Ki67, but not neuroendocrine expression, is an independent factor in the prediction of prognosis of primary prostate cancer patients;Radiology and Oncology;2016-07-19

4. Prospective study on the relationship between clinical efficacy of secondary hormone therapy with flutamide and neuroendocrine differentiation in patients with relapsed prostate cancer after first line hormone therapy;Scandinavian Journal of Urology;2014-04-15

5. Ellagic Acid: Cytodifferentiating and Antiproliferative Effects In Human Prostatic Cancer Cell Lines;Current Pharmaceutical Design;2013-03-01